NCT06280495 2026-04-20
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
Sun Yat-sen University
Phase 2/3 Recruiting
Clinical Trials
7 trialsNCT07472153 2026-03-16
PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
N.N. Alexandrov National Cancer Centre
Phase 2/3 Recruiting
NCT07319429 2026-03-13
FEMUS
Fudan University
Phase 2/3 Recruiting
NCT04864782 2024-01-12
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 2/3 Terminated
NCT05605613 2022-11-09
PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial
The First Affiliated Hospital of Zhengzhou University
Phase 2/3 Unknown
NCT04973306 2022-06-30
iCROSS
Shanghai Zhongshan Hospital
Phase 2/3 Recruiting
NCT03975036 2019-06-05
Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody
Henan Cancer Hospital
Phase 2/3 Unknown